
WHAT IS CLAIMED IS:



10

15

25

30

wherein R^a and R^b are independently selected from H, halo, cyano, -NHR⁶ and C_{1-4} -alkyl substituted with R^1 , or wherein R^a and R^b together form C_3 - C_6 cycloalkyl;

wherein R^z is selected from C_2 - C_6 -alkylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-group; wherein one of the CH_2 groups may be substituted with one or two radicals selected from halo, cyano, -NHR⁶ and C_{1-4} -alkyl substituted with R^1 ;

wherein Rd is cycloalkyl;

wherein R¹ is one or more substituents independently selected from H halo, -OR², oxo, -SR², -CO₂R², -COR², -CONR²R², -NR²R², -SO₂NR²R², -NR²C(O)OR², -NR²C(O)R², optionally substituted cycloalkyl, optionally substituted phenylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted phenyl, lower alkyl, cyano, lower hydroxyalkyl, lower carboxyalkyl, nitro, lower alkenyl, lower alkynyl, lower aminoalkyl, lower alkylaminoalkyl and lower haloalkyl;

20 wherein R² is selected from

- a) substituted or unsubstituted 6-10 membered aryl,
- b) substituted or unsubstituted 5-6 membered heterocyclyl,
- c) substituted or unsubstituted 9-14 membered bicyclic or tricyclic heterocyclyl,
- d) cycloalkyl, and
- e) cycloalkenyl,

wherein substituted R^2 is substituted with one or more substituents independently selected from halo, $-OR^7$, OXO, $-SR^7$, $-CO_2R^7$, $-CONR^7R^7$, $-COR^7$, $-NR^7R^7$, $-NH(C_1-C_4$ alkylenyl R^9), $-SO_2R^7$, $-SO_2NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, $-NR^7C(O)NR^7R^7$, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted phenyl, halosulfonyl, cyano,

TU

alkylaminoalkoxy, alkylaminoalkoxyalkoxy, nitro, lower

Cl La

| 4 []

O

TU

alkyl substituted with R1, lower alkenyl substituted with R^1 , and lower alkynyl substituted with R^1 ; wherein R3 is selected from aryl unsubstituted or 5 substituted with one or more substituents independently selected from halo, -OR7, -SR7, -SO2R7, -CO2R7, -CONR7R7, $-COR^{7}$, $+NR^{7}R^{7}$, $-SO_{2}NR^{7}R^{7}$, $-NR^{7}C(0)OR^{7}$, $-NR^{7}C(0)R^{7}$, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted phenyl, nitro, 10 alkylaminoalkoxyalkoxy, cyano, alkylaminoalkoxy, lower alkyl substituted with R1, lower alkenyl substituted with R¹, and lower alkynyl substituted with R¹; wherein R^4 is selected from a direct bond, C_{2-4} -alkylenyl, C_{2-1} $_4$ -alkenylenyl and C_{2-4} -alkynylenyl, where one of the CH_2 groups may be substituted with an oxygen atom or an -NH-, 15 wherein R4 is optionally substituted with hydroxy; wherein R⁵ is selected from H, lower alkyl, optionally substituted phenyl\and lower aralkyl; wherein R^{5a} is selected from H, lower alkyl, optionally 20 substituted phenyl and lower aralkyl; wherein R^6 is selected from H or C_{1-6} -alkyl; and wherein R7 is selected from H, lower alkyl, optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted $C_3 - C_6$ -cycloalkyl, optionally 25 substituted phenyl-C₁₋₆-alkyl, optionally substituted heterocyclyl-C₁₋₆-alkyl, optionally substituted C₃-C₆

wherein R9 is selected from H, opt\u00e4onally substituted phenyl, optionally substituted 5\6 membered heterocyclyl and optionally substituted C3-C6 cxcloalkyl; and pharmaceutically acceptable derivatives thereof; provided R2 is not 3-trifluoromethylphenyl when A is pyridyl, when X is -C(0)NH-, when χ is $-NH-CH_2-$, when

 $\label{eq:cycloalkyl-C1-6-alkyl, alkylam} in oalkyl, and lower$

30

haloalkyl;

ļ

O N 10

R¹ is H and R³ is 3-(N-methylamino-carbonyl)phenyl, 4-hydroxyphenyl, 3-hydroxyphenyl or phenyl;


- further provided R² is not substituted with -SO₂NR⁷R⁷ when Y is NHSO₂-;
- further provided R^2 is not 3-trifluoromethylphenyl when A is pyridyl, when X is -C(0)NH-, when Y is $-N(benzyl)-CH_2-$, when R is H and when R^3 is phenyl;
 - further provided R^2 is not cyclohexyl when A is pyridyl, when X is -C(O)NH-, when Y is $-NH-CH_2-$, when R^1 is H and when R^3 is 2-methoxyphenyl or 3-methoxyphenyl;
 - further provided R¹ is not 2-hydroxymethylpyrrol-5-yl when A is pyridyl;
 - further provided R is not 4-


(methoxyaminodarbonylamino)phenyl when A is thienyl;

- further provided R^1 is not 2-pyridylmethoxy when A is pyrimidyl, when X is -C(0)NH-, and when Y is $-NH-CH_2-$;
 - further provided R^1 is not 4-methylpiperidyl when A is pyrimidyl, when X is -C(0)NH-, when Y is $-NH-CH_2-$, and when R^3 is 3-chloro-4-methoxyphenyl;
- further provided R¹ is not bromo when A is pyrimidyl, when X is -C(0)NH-CH₂-, when Y is -NH-CH₂-, and when R³ is 3-chloro-4-methoxyphenyl;
 - further provided R^2 is not 2-chloro-3-pyridyl when A is pyridyl; and
- 25 further provided R^2 is not 2-methoxyphenyl when A is pyridyl, when X is -C(O)NH, when Y is $-NH-CH_2-$, when R^1 is H and R^3 is phenyl.
- 2. Compound of Claim 1 wherein A is selected from thienyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyrazolyl, isoxazolyl, triazolyl, isothiazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl; wherein X is selected from

20

25





R⁵
|
|
|
|
|
|
|
|
|
|
|
|

wherein R^a and R^b are independently selected from H, halo, and C_{1-2} -alkyl substituted with R^1 , or wherein R^a and R^b together form C_3 - C_4 cycloalkyl;

wherein R^z is C_2-c_3 alkylenyl, where one of the CH_2 groups may be replaced with an oxygen atom or an -NH-;

wherein R¹ is one or more substituents independently selected from H, halo, -OR⁷, oxo, -SR⁷, -CO₂R⁷, -CONR⁷R⁷, -COR⁷, -NR⁷R⁷, -SO₂NR⁷R⁷, -NR⁷C(O)OR⁷, -NR⁷C(O)R⁷, optionally substituted C₃₋₆-cycloalkyl, optionally substituted phenyl-C₁₋₄-alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted the phenyl, optionally substituted phenyl, optionally substituted the phenyl, optionally substituted the phenyl, optionally substituted the phenyl, optionally substituted the phenyl optionally subst

neterocycly1, optionalty substituted pheny1, optionalty substituted 4-6 membered heterocycly1- C_{1-4} -alky1, C_{1-6} -alky1, cyano, C_{1-4} -hydroxyalky1, C_{1-4} -carboxyalky1, nitro, C_{2-3} -alkeny1, C_{2-3} -alkyny1 and C_{1-4} -haloalky1;

wherein R^2 is selected from

substituted or unsubstituted aryl selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl, substituted or unsubstituted 5-6 membered heteroaryl, substituted or unsubstituted C₃-c-cycloalkyl and substituted or unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic saturated or partially

13-14 membered tricyclic saturated or partially unsaturated heterocyclyl

wherein substituted R^2 is substituted with one or more substituents independently selected from halo, $-\mathrm{OR}^7$, oxo,

The the test of the tests

O

O

TU:

TU .

 $-SR^7, -SO_2R^7, -CO_2R^7, -CONR^7R^7, -COR^7, -NR^7R^7, -NH(C_1-C_2-R) \\ = -SR^7, -SO_2R^7, -CO_2R^7, -CONR^7R^7, -SO_2NR^7R^7, -NH(C_1-C_2-R) \\ = -SR^7, -SO_2R^7, -COR^7, -NH(C_1-C_2-R) \\ = -SR^7, -SO_2R^7, -SO_2R^7, -NH(C_1-C_2-R) \\ = -SR^7, -SO_2R^7, -SO_2R^7,$

optionally substituted C_{3-6} -cycloalkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted phenyl, optionally substituted phenyl- C_{1-6} -alkylenyl, optionally substituted 4-6 membered heterocyclyl- C_{1-6} -alkylenyl, 4-6 membered heterocyclyl- C_{2-1} -C₆-alkylenyl, 4-6 membered heterocyclyl- C_{2-1} -C₆-alkenylenyl, C_{1-4} -alkyl, cyano, C_{1-4} -hydroxyalkyl, nitro and C_{1-4} -haloalkyl;

wherein R^3 is phenyl substituted with one or more substituents independently selected from halo, $-OR^7$, $-SR^7$, $-CO_2R^7$, $-CONR^7R^7$, $-COR^7$, $-NR^7R^7$, $-SO_2NR^7R^7$, $-NR^7C(O)OR^7$, $-NR^7C(O)R^7$, C_{3-6} -cycloalkyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted phenyl, C_{1-4} -alkyl, C_{1-4} -aminoalkyl, cyano, C_{1-4} -hydroxyalkyl, nitro and C_{1-4} -haloalkyl;

wherein R^{4a} is C_{2-4} -alkylenyl where one of the CH_2 groups may be replaced with an oxygen atom or -NH-, wherein R^{4a} is optionally substituted with hydroxy;

wherein R5 is selected from H and C1-C2-alkyl;

wherein R^{5a} is selected from H and C₁₋C₂-alkyl; and wherein R⁷ is selected from H, C₁₋₄ alkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋₄-alkyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C₁₋₄-alkyl, optionally substituted C₃-C₆ cycloalkyl, C₁₋₂-alkylamino-C₁₋₄-alkyl and C₁₋₂-haloalkyl,

wherein R^e and R^f are independently selected from H and C_{1-2} -haloalkyl; and

10

15

20

5

10

15

25

ļi

O TU wherein R^g is selected from H, C₁₋₆-alkyl, optionally substituted phenyl- C_{1-6} -alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C1-C6alkyl \setminus C₁₋₄-alkoxy-C₁₋₄-alkyl and C₁₋₄-alkoxy-C₁₋₄-alkoxy-C₁₋ ₄-alkyl

and pharmaceutically acceptable derivatives thereof.

3. Compound of Claim 2 wherein A is selected from

pyridyl and pyrimidinyl; wherein X is ; wherein Y is -NH-CH₂-; wherein R¹ is one or more substituents independently selected from H, halo, hydroxy, C_{1-2} -alkoxy, C_{1-2} -haloalkoxy, amin \dot{Q} , C_{1-2} -alkylamino, optionally substituted 5-6 membered heterocyclyl-C₁₋₂-alkylamino, aminosulfonyl, C₃₋₆-cycloalkyl, optionally substituted 5-6

membered heterocyclyl, optionally substituted phenyl, C_{1-4} alkyl, cyano, C_{1-2} -hydroxyalkyl, C_{1-3} -carboxyalkyl, nitro, C_{2-1} $_3$ -alkenyl, C_{2-3} -alkynyl and C_{1-2} -haloalkyl; wherein R^2 is unsubstituted or substituted and selected from phenyl, naphthyl, indanyl, indenyl and tetrahydronaphthyl,

20 substituted or unsubstituted 5/6 membered heteroaryl, C_{3-6} cycloalkyl, and substituted or \unsubstituted 9-10 membered bicyclic or 13-14 membered tricyclic heterocyclyl; wherein substituted R^2 is substituted with one or more substituents independently selected from halo, q_{1-4} -alkyl, optionally

substituted C₃₋₆-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl- C_1 - C_4 -alkylenyl, C_{1-2} haloalkoxy, optionally substituted phe yloxy, optionally substituted 5-6 membered heterocyclyl-C\C₄-alkylenyl, optionally substituted 5-6 membered heterocyclyl-C2-C4-

30 alkenylenyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted 5-6 membered heterocyclyloxy, optionally substituted 5-6 membered

10

15

20

25

30

fU.

heterocyclylsulfonyl, optionally substituted 5-6 membered heterocyclylamino, optionally substituted 5-6 membered heterocyclylcarbonyl, optionally substituted 5-6 membered heterocyclyl- C_{1-4} -alkylcarbonyl, C_{1-2} -haloalkyl, C_{1-4} -aminoalkyl, nitro, amino, hydroxy, cyano, aminosulfonyl, C_{1-2} -alkylsulfonyl, halosulfonyl, C_{1-4} -alkylcarbonyl, C_{1-3} -alkylamino- C_{1-3} -alkyl, C_{1-3} -alkylamino- C_{1-3} -alkoxy, C_{1-3} -alkylamino- C_{1-3} -alkoxy- C_{1-3} -alkoxy, C_{1-4} -alkoxycarbonyl, C_{1-4} -

alkoxycarbonylamino- C_{1-4} -alkyl, C_{1-4} -hydroxyalkyl, and C1-4-alkoxy; wherein R3 is phenyl substituted with one or more substituents independently selected from halo, hydroxy, C_{1-4} -alkyl, C_{1-2} -alkoxy, optionally substituted 5-6 membered heterocyclyl- C_{1-2} -alkoxy, amino, C_{1-2} -alkylamino, aminosulfonyl, $-NR^3C(0)OR^7$, $-NR^3C(0)R^7$, C_{3-6} -cycloalkyl, optionally substituted \S -6 membered heterocyclyl, optionally substituted phenyl, nitro C_{1-2} -alkylamino- C_{1-2} -alkoxy- C_{1-2} alkoxy, cyano, C₁₋₂-alkylamino-C₁₋₂-alkoxy, C₁₋₂-alkylamino-C₁₋ $_2$ -alkyl, C_{1-2} -alkylamino- C_{2-3} -alkynyl, C_{1-2} -hydroxyalkyl, C_{1-2} aminoalkyl, C₁₋₂-haloalkyl, optionally substituted 5-6 membered heterocyclyl-C2-3-alkenyl, and optionally substituted 5-6 membered heterocyclyl- C_{2-3} -alkynyl; and wherein R⁷ is selected from H, methyl, phenyl, cyclopropyl, cyclohexyl, benzyl, morpholinylmethyl, 4methylpiperazinylmethyl, 4-methylpiperdinylmethyl, 4morpholinylmethyl, 4-morpholinylethyl \setminus 1-(4-morpholinyl)-2,2-dimethylpropyl, 1-piperdinylethyl, \1-piperdinylpropyl, 1-pyrrolidinylpropyl and trifluoromethyl \setminus wherein R^e and R^f are independently -CF3; and wherein R9 is alelected from H, C_{1-3} -alkyl, optionally substituted phenyl- C_{1-1} -alkyl,

optionally substituted 5-6 membered heterocy Δ lyl-C₁₋C₃-alkyl,

 C_{1-3} -alkoxy- C_{1-3} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl;

and pharmaceutically acceptable derivatives the teof.

10

15

20

25

35

14

卢스

O

TU:

. Compound of Claim 3 wherein A is pyridyl; wherein R1 is one or more substituents independently selected from H, chloro, and fluoro; wherein R2 is selected from phenyl, tetrahydronaphthyl, indanyl, naphthyl, imidazolyl, oxazolyl, furyl, pyrrolyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiazolyl thienyl, pyridyl, pyrimidinyl, pyridazinyl, cyclohexyl, $1\2$ -dihydroquinolyl, 1,2,3,4-tetrahydroisoquinoly1, $1\2$,3,4-tetrahydro-quinoly1, 2,3-dihydro-1Hindolyl, 2,3,4, a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7trihydro-1,2,4-thiazolo[3,4-a]isoquinolyl, 3,4-dihydro-2Hbenzo[1,4]oxaziny1, and benzo[1,4]dioxanyl; wherein substituted R2 is substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, methylpiperazinylmethyl, morpholinylethyl, methylpiperazinylpropyl, \(\frac{1}{4} - (4 - morpholinyl) - 2, 2 dimethylpropyl, piperidinylmethyl, morpholinylpropyl, methylpiperidinylmethyl, piperidinylethyl, piperidinylpropyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, piperidinylmethylcarbonyl, methylpiperazinylcarbonylethyl, methoxycarbonyl, 3ethoxycarbonyl-2-methyl-fur-5-yl methylpiperazinyl, methylpiperidyl, 1-methyl-(1,2,3,6-tetrahydropyridyl), imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl isopropyl, butyl, tertbutyl, sec-butyl, trifluoromethyl, pentafluoroethyl, 30 nonafluorobutyl, dimethylaminopropyl, \1,1di(trifluoromethyl)-1-hydroxymethyl, taifluoromethoxy, 1,1di(trifluoromethyl)-1-(piperidinylethoxy) methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy) methyl, 1hydroxyethyl, 2-hydroxyethyl, 1-aminoethyl 2-aminoethyl, 1-

(N-isopropylamino) ethyl, 2-(N-isopropylamino) ethyl,

20

30

dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, 1-methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and wherein R³ is phenyl substituted with one or more substituents selected from chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, amino, dimethylamino, diethylamino, 1-methylpiperidinylmethoxy, aminosulfonyl, cyclohexyl, dimethylaminopropynyl, dimethylaminoethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminoethoxy, optionally substituted piperidinyl, morpholinyl, optionally substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro and trifluoromethyl; and pharmaceutically acceptable derivatives thereof.

5. Compound of Claim 1 and pharmaceutically acceptable derivatives thereof selected from

```
'N-(4-Chlorophenyl){3-[benzylamino](2-pyridyl)}carboxamide;
```

- N-(4-Chlorophenyl)(3-{[\d-nitrophenyl)methyl]amino}(2-pyridyl))-carboxamide;
- (2-[[(4-methoxyphenyl)methyl]amino](2-pyridyl))-N-(3-fluoro-4-methylphenyl)carboxamide;
 - (6-Chloro-2-[[(4-methoxyphenyl)methyl]amino[(3-pyridyl))-N-(3-fluoro-4-methylphenyl)carboxamide;
- 25 (6-Chloro-2-[[(4-methoxyphenyl)methyl]amino[(3-pyridyl))-N-(3-fluoro-4-methylphenyl)carboxamide;
 - (6-Chloro-2-[[(4-methoxyphenyl)methyl]amino[(3-pyridyl))-N-(3-fluoro-4-methylphenyl)carboxamide, hydrochloride;
 - (6-Chloro-2-{[(4-methoxyphenyl)methyl]amino}(3-pyridyl))-N-(4-chlorophenyl)carboxamide;
 - 2-(3-Fluoro-benzylamino)-N-(4-phenoxy\phenyl)-nicotinamide;
 - N-(4-Phenoxyphenyl)[2-({[3-

(trifluoromethyl)phenyl]methyl}amino) (3pyridyl)]formamide;

```
A-735A
                                  - 239 -
     (2 + {[(4-Fluorophenyl)methyl]amino}(3-pyridyl))-N-(4-
        phenoxyphenyl) formamide;
     N-(4-Phenoxyphenyl)[2-({[4-
        (trafluoromethyl)phenyl]methyl)amino)(3-
        pyridyl)]formamide;
     (2-\{[(2-B_{romophenyl}) methyl] amino\}(3-pyridyl))-N-(4-
        phenoxyphenyl) formamide;
    N-(4-Phenoxyphenyl)[2-({[4-
        (trifluoromethoxy)phenyl]methyl}amino)(3-
10
       pyridyl)]formamide;
     2-{[(2,3-Difluorophenyl)methyl]amino}(3-pyridyl))-N-(4-
       phenoxyphenylformamide;
    N-(4-Chlorophenyl)\\ 2-\{ [(4-cyanophenyl) methyl] amino\}(3-
       pyridyl))carboxamide
    N-(4-Chlorophenyl) (2) ((12-)cyanophenyl) methyl] amino) (3-
15
       pyridyl))carboxa#ide;
    N-(4-sec-butylphenyl) /2 [(4-fluorobenzyl) amino] nicotinamide;
    N-(4-tert-Butylphenyl)-2 [(4-
        fluorobenzyl)amino]nicdtinamide;
20
    N-(4-Isopropyl-phenyl)-2-(\frac{1}{4}-methoxy-benzylamino)-
       nicotinamide;
     (2-{[(4-Fluorophenyl)methyl]amino}(3-pyridyl))-N-[4-
        (methylethyl)phenyl]carboxamide;
     (2-{[(4-Fluorophenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
25
     (2-{[(3,4-Dimethoxyphenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
     {2-[Benzylamino](3-pyridyl)}-N-[3-(trifluoromethyl)phenyl]-
       carboxamide;
30
      (2-{[(3-Chlorophenyl)methyl]amino}(3\pyridyl))-N-[3-
        (trifluoromethyl) phenyl] carboxamide;
     (2-{[(4-Bromophenyl)methyl]amino}(3-pyri\dyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
```

```
\(2-{[(4-Chlorophenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
     (2-\{(2,4-Difluorophenyl)methyl]amino\}(3-pyridyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
 5
      (2-\{[(4\Fluorophenyl)ethyl]amino\}(3-pyridyl))-N-[3-
        (trifluoromethyl) phenyl] carboxamide;
     (2-\{[(3,4-Difluorophenyl)methyl]amino\}(3-pyridyl))-N-[3-
        (trifluor@methyl)phenyl]carboxamide;
     (2-\{[(2,3-Dif]uorophenyl)methyl]amino\}(3-pyridyl))-N-[3-
10
        (trifluoromethyl)phenyl]carboxamide;
     (2-{[(2-Fluorophenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethx1)phenyl]carboxamide;
     (2-{[(2,6-Difluoromhenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethyl) phenyl] carboxamide;
15
     (2-{[(3-Bromophenyl)methyl]amino}(3-pyridyl))-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
     (2-\{[(4-Fluorophenyl)me(hy)]amino\}(3-pyridyl))-N-[4-
        (trifluoromethyl)phehy/]carboxamide;
    N-{3-[3-(Dimethylamino)propyl]-5-(trifluoromethyl)phenyl}(2-
20
        {[(4-fluorophenyl)methyl\amino}(3-pyridyl))carboxamide;
     \{2-[(\{3-[3-(Dimethylamino)propyl]-4-
        fluorophenyl}methyl)amino](3-pyridyl)}-N-[4-(tert-
       butyl)phenyl]carboxamide;
     \{2-[(\{3-[3-(Dimethylamino)propy]\}]-4-
        fluorophenylmethyl)amino(3-hyridyl)-N-[4-
25
        (trifluoromethyl)phenyl]carboxamide;
     \{2-[(\{3-[3-(Dimethylamino)propyl]-\}\}]\}
        fluorophenyl}methyl)amino](3-pyri\dyl)}-N-(4-bromo-2-
        fluorophenyl)carboxamide;
30
     2-[(4-Fluorobenzyl)amino]-N-[4-tert-butyl-3-(1,2,3,6-
        tetrahydropyridin-4-yl)phenyl]nicotihamide;
      [2-(\{[4-Fluoro-3-(3-morpholin-4-ylprop-1-
       ynyl)phenyl]methyl}amino)(3-pyridyl)]-N-[3-
        (trifluoromethyl)phenyl]carboxamide;
```

```
{2-\((2H-Benzo[d]1,3-dioxol-5-ylmethyl)amino](3-pyridyl)}-N-
(4-phenoxyphenyl)carboxamide;
```

- 2-(4-hluoro-benzylamino)-N-[3-(2-pyrrolidin-1-yl-ethoxy)-4-trifluoromethyl-phenyl]-nicotinamide;
- 5 2-(4-Fluoro-benzylamino)-N-[3-(1-Boc-pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotinamide;
 - N-[4-tert-Butyl-3-(1-Boc-piperidin-4-ylmethoxy)-phenyl]-2-(4-fluord-benzylamino)-nicotinamide;
- N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-yl)-2,3-dihydro-1Hindol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
 - N-[1-(2-Dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2 (4-fluoro-benzylamino)-nicotinamide;
 - N-[1-(1-Boc-piperidin-4-yl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(4-flyoro-benzylamino)-nicotinamide;
- N-[3,3-Dimethyl-1-(2/Boc-amino-acetyl)-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;
 - 2-(4-Fluoro-benzylamino)-N-(2-Boc-4,4-dimethyl-1,2,3,4-tetrahydro-isoquino)in-7-yl)-nicotinamide;
- N-[3-(1-Boc-pyrrolidin 2-ylmethoxy)-5-trifluoromethyl-20 phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(1-Boc-pyrrolidin-2-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
 - N-(4-Acetyl-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-2-(4-fluoro-benzylamino)-nicotinamide;
- 25 2-(4-Fluoro-benzylamino)-N-[3-(1-Boc-piperidin-4-ylmethoxy)-5-trifluoromethyl phenyl]-nicotinamide.;
 - 2-(4-Fluoro-benzylamino)-N-[3-(pyrrolidin-2-ylmethoxy)-4-pentafluoroethyl-phenyl]-nicotynamide;
 - 2-(4-Fluoro-benzylamino)-N-[3-(pyrolidin-2-ylmethoxy)-5trifluoromethyl-phenyl]-nicotinanide;
 - N-[4-tert-Butyl-3-(piperidin-4-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;
 - N-[4-tert-Butyl-3-(pyrrolidin-2-ylmethoxy)-phenyl]-2-(4-fluoro-benzylamino)-nicotinamide;

ru

N-14,4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)-2-(4-fluoro-benzylamino)-nicotinamide;

N-[1-(2-Amino-acetyl)-3,3-dimethyl-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;

5 N-(3,3-Dimethyl-1-piperidin-4-yl-2,3-dihydro-1H-indol-6-yl)-2-(4-fluoro-benzylamino)-nicotinamide;

2-(4-Fluoro-benzylamino)-N-[3-(piperidin-4-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;

N-(2,2-Dimwethyl-3,4-dimydro-2H-benzo[1,4]oxazin-6-yl)-2-(4-fluoro-benzylamino)-niotinamide;

2-(4-Fluoro-benzylamino)-N-(3-(1-methyl-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-nicotinamide;


N-[3,3-Dimethyl-1-(1-methyl-piperidin-4-ylmethyl)-2,3-dihydro-1H-indol-6-yl]-2-(4-fluoro-benzylamino)-nicotinamide;

2-(4-Fluoro-benzylamino)-N-{4-[1-methyl-1-(1-methyl-piperidin-4-yl)-ethyl]-phenyl}-nicotinamide;

N-(4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl)-2-(4-fluoro-benzylamino)-nicotinamide; and

20 3-Benzo[1,3]dioxol-5-yl-3-[3-(4-pentafluoroethyl-phenylcarbamoyl)-pyridin-2-ylamino]-propionic acid.

6. Compound of Claim 1 of formula II'



25

10

15

wherein each of A^3 and A^4 is independently CH or N, provided at least one of A^3 and A^4 is N; wherein n is 1-2;

II'

10

15

20

25

30

wherein R¹ is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, trifluoromethoxy, oxo, amino, dimethylamino, aminosulfonyl, carboxymethyl, cyclopropyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, nitro, propenyl, propynyl, morpholinylethylamino, trifluoromethyl and unsubstituted or substituted heteroaryl selected from thienyl, furanyl, pyridyl, imidazolyl and pyrazolyl;

wherein R² is selected from a substituted or unsubstituted ring selected from phenyl, tetrahydronaphthyl, indanyl, benzodioxolyl, indenyl, naphthyl, isoxazolyl, pyrazolyl, thiazolyl, thiadiaxolyl, thienyl, pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3,4-tetrahydro-quinolyl, isoquinolyl, quinolyl, indolyl, isoquinolyl, 2,3-dihydro-1H-indolyl, naphthyridinyl, quinozalinyl, 2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluorenyl, 5,6,7-trihydro-1,2,4-triazolo[3,4-a]isoquinolyl, indazolyl, 2,1,3-benzothiadiazolyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, benzodioxanyl, benzothienyl, benzofuryl, benzimidazolyl, benzoxazolyl and benzthiazolyl;

wherein substituted R² is substituted with one or more substituents independently selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-methylpiperidin-4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-

O

TU:

10

15

20

25

30

piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Bocpiperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Bocpiperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Bocpyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4-methylpiperazin-1ylcarbonylethyl, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, 3-ethoxycarbonyl-2methyl-fur-5-y\, 4-methylpiperazin-1-yl, 4-methyl-1piperidyl, 1-Boc 4-piperidyl, piperidin-4-yl, 1methylpiperidin-4\yl, 1-methyl-(1,2,3,6tetrahydropyridyl) λ imidazolyl, morpholinyl, 4trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, secbutyl, trifluoromethyl\ pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1di(trifluoromethyl)-1-hydroxymethyl, 1,1di(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1di(trifluoromethyl)-1-(methoxyethoxyethoxy)methyl, 1hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1aminoethyl, 2-aminoethyl, 1-(N\isopropylamino)ethyl, 2-(N-isopropylamino)ethyl, dimethylaminoethoxy, 4chlorophenoxy, phenyloxy, azetidih-3-ylmethoxy, 1-Bocazetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Bocpyrrol-2-ylmethoxy, pyrrol-1-ylmeth xy, 1-methylpyrrol-2-ylmethoxy, 1-isopropyl-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, 1methylpiperdin-4-yloxy, isopropoxy, methoxy and ethoxy; and wherein R⁸ is one or more substituents independently

selected from H, chloro, fluoro, bromo, hydroxy, methoxy,

10

15

20

ethoxy, -O-CH₂-O-, trifluoromethoxy, 1methylpiperidinylmethoxy, dimethylaminoethoxy, amino,
dimethylamino, dimethylaminopropyl, diethylamino,
aminosulfonyl, cyclohexyl, dimethylaminopropynyl, 3-(4morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, 3-(4morpholinyl)propylamino, optionally substituted
piperidinyl, morpholinyl, optionally substituted
piperazinyl, optionally substituted phenyl, methyl,
ethyl, propyl, cyano, hydroxymethyl, aminomethyl, nitro
and trifluoromethyl;

provided R² is not 3-trifluoromethylphenyl when A³ is N, when A⁴ is CH, when n is 1, when R¹ is H and R⁸ is 4-hydroxy, 3-hydroxy or H; further provided R² is not 2-chloro-3-pyridyl when A³ is N, when A⁴ is CH, when n is 1, when R¹ is H and R⁸ is H or 4-methoxy; and further provided R² is not 2-methoxyphenyl when A³ is N, when A⁴ is CH, when n is 1 when R¹ is H and R⁸ is H.

7. Compound of Claim 1 of Formula III

R¹ 15 3 NH R² NH

wherein R¹ is one or more substituents independently selected from

25 H, halo, hydroxy, amino, $C_{1-6}-alkyl$,

 C_{1-6} -haloalkyl,

ľU.

20

25

30

```
C_{1-6}-alkoxy,
                   C_{1-2}-alkylamino,
                   aminosulfonyl,
                   C3-6-cycloalkyl,
 5
                    cyano,
                   oko,
                   C_1 \searrow -hydroxyalkyl,
                   nitko,
                   C_{2-3}-alkenyl,
10
                   C_{2-3}-a\lambda kynyl,
                   C_{1-6}-haloalkoxy,
                   C_{1-6}-carboxyalkyl,
                   5-6-membered heterocyclyl-C<sub>1-6</sub>-alkylamino,
                   unsubstituted or substituted phenyl and
                   unsubstituted or substituted 5-6 membered
15
                      heterocyclyl;
```

wherein R² is selected from unsubstituted or substituted phenyl, and
9-10 membered picyclic and 13-14 membered tricyclic unsaturated or partially unsaturated peterocyclyl,

wherein substituted R² is optionally substituted with one or more substituents selected from halo, C₁₋₆-alkyl, optionally substituted C₃₋₆-cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C₁₋ C₄-alkyl, C₁₋₂-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-C₁₋C₄-alkyl, optionally substituted 4-6 membered heterocyclyl-C₂₋C₄-alkenyl, optionally substituted 5-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-C₁₋C₄-alkoxy, optionally substituted 5-6 membered heterocyclyl-C₁₋C₄-alkoxy, optionally substituted 5-6 membered heterocyclylsulfonyl, optionally substituted 5-6

10

15

20

25

30

m

Ü

TLI

membered heterocyclylamino, optionally substituted 5-6 membered heterocyclylcarbonyl, optionally substituted 5-6 membered heterocyclylcarbonyl-C₁₋₄-alkyl, optionally substituted 5-6 membered heterocyclyl-C₁₋₄-alkylcarbonyl, C₁₋₄-haloalkyl, C₁₋₄-aminoalkyl, nitro, amino, hydroxy, oxo, cyano, aminosulfonyl, C₁₋₂-alkylsulfonyl, halosulfonyl, C₁₋₄-alkylcarbonyl, amino-C₁₋₄-alkylcarbonyl, C₁₋₄-alkylamino-C₁₋₄-alkylcarbonyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₄-alkylamino-C₁₋₃-alkylamino-C₁₋₃-alkoxy, C₁₋₄-alkoxycarbonyl, C₁₋₄-alkoxycarbonylamino-C₁₋₄-alkyl, C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl, C₁₋₄-alkylamino-C₁₋₄-alkyl

4-hydroxyalkyl,

and C_{1-4} -alkoxy;

wherein R^e and R^f are independently selected from H and C_{1-2} haloalkyl;

wherein R⁷ is selected from H, C₁₋₃-alkyl, optionally substituted phenyl-C₁₋₃-alkyl, 4-6 membered heterocyclyl, and optionally substituted 4-6 membered heterocyclyl-C₁₋C₃-alkyl;

wherein R^g is selected from H, C_{1-3} -alkyl, optionally substituted phenyl- C_{1-3} -alkyl, 4-6 membered heterocyclyl, and optionally substituted 4-6 membered heterocyclyl- $C_{1-}C_{3}$ -alkyl, C_{1-3} -alkoxy- C_{1-2} -alkyl and C_{1-3} -alkoxy- C_{1-3} -alkoxy- C_{1-3} -alkyl; and

wherein R^8 is one or more substituents independently selected from H, halo, amino, hydroxy, C_{1-6} -alkyl, C_{1-6} -haloalkyl, C_{1-6} -alkoxy, C_{1-6} -haloalkoxy, C_{1-6} -aminoalkyl, C_{1-6} -hydroxyalkyl, optionally substituted phenyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl- C_{1-6} -alkoxy, aminosulfonyl, C_{3-6} -cycloalkyl, C_{1-6} -alkylamino, C_{1-6} -alkylamino- C_{1-6} -alkylamino, optionally substituted heterocyclyl- C_{1-6} -alkylamino, optionally substituted heterocyclyl- C_{1-6} -alkylamino, C_{1-6} -alkylamino- C_{2-4} -

alkynyl, C_{1-6} -alkylamino- C_{1-6} -alkoxy, C_{1-6} -alky Λ amino- C_{1-6} -

a

fU

alkoxy-C₁₋₆-alkoxy, and optionally substituted $heterocyclyl-C_{2-4}-alkynyl;$

and pharmaceutically acceptable isomers and derivatives thereof:

provided R2 is not 3-trifluoromethylphenyl when R1 is H and 5 R⁸ is 4-hydroxy, 3-hydroxy or H; and further provided R^2 is\not 2-methoxyphenyl when R^1 is H and R^8 is H.

8. Compound of Claim 7 wherein R1 is selected from H, chloro, fluoro,\bromo, amino, hydroxy, methyl, ethyl, propyl, oxo, dimathylamino, aminosulfonyl, cyclopropyl, cyano, hydroxymethyl, nitro, propenyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, carboxymethyl, morpholinylethylamind, propynyl, unsubstituted or substituted phenyl and unsubstituted or substituted heteroaryl selected from thienyl,

furanyl, pyridyl, imidazolyl, and pyrazolyl; wherein R^2 is selected from phenyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydro-isoquinoly1, 1,2,3,4-tetrahydroquinolyl, 2.3-dihydro-1H- $\frac{1}{3}$ ndolyl, 2.3.4.4a.9.9ahexahydro-1H-3-aza-fluoren 1, 5,6,7-trihydro-1,2,4 $triazolo[3,4-a]isoquinolyl, \3,4-dihydro-2H$ benzo[1,4]oxazinyl, and benz λ [1,4]dioxanyl, where R² is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, aminoethyl, Boc-aminoethyl, hydroxy, oxo, aminosulfonyl, 4-methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, morpholinylmethyl, 1methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1methylpiperidin-4-ylmethyl, 2-methyl-2 + (1methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Bocpiperidin-4-ylethyl, piperidin-4-ylmethyl, \1-Boc-

10

15

20

25

30

35

piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Bocpiperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1ylaropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc\pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrol\dinylbutenyl, fluorosulfonyl, methylsulfonyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, 4methylpiperazin-1-ylcarbonylethyl, methoxycarbonyl, aminomethy\{carbonyl, dimethylaminomethylcarbonyl, 3ethoxycarbomyl-2-methyl-fur-5-yl, 4-methylpiperazin-1-yl, 4-methyl-1-p $rac{1}{2}$ peridyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methylpiperidin-4-yl, 1-methyl-(1,2,3,6tetrahydropyridyl), imidazolyl, morpholinyl, 4trifluoromethyl 1-piperidinyl, hydroxybutyl, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl 1,1-di(trifluoromethyl)-1hydroxymethyl, 1,1-d\(\frac{1}{4}\)(trifluoromethyl)-1-(piperidinylethoxy)methyl, 1,1-di(trifluoromethyl)-1-(methoxyethoxyethoxy) methyl, 1-hydroxyethyl, 2hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2aminoethyl, 1-(N-isopropylamino)ethyl, 2-(Nisopropylamino) ethyl, dimethylaminoethoxy, 4chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, 1-Bocazetidin-3-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2ylmethoxy, pyrrol-1-ylmethoxy 1-methyl-pyrrol-2ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4ylmethoxy, 1-methylpiperdin-4-y\oxy, isopropoxy, methoxy and ethoxy; and

wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, hydroxy, methoxy, ethoxy, -O-CH₂-O-, trifluoromethoxy, 1-methylpiperidinylmethoxy, dimethylaminoethoxy, amino, dimethylamino, dimethylaminopropyl, diethylamino,

sh Bi

10

5

15

20

25

3.0

5 Jb Bl aminosulfonyl, cyclohexyl, dimethylaminopropynyl, 3-(4-morpholinyl)propyn-1-yl, dimethylaminoethoxyethoxy, 3-(4-morpholinyl)propylamino, optionally substituted piperidinyl, morpholinyl, optionally substituted piperazinyl, optionally substituted phenyl, methyl, ethyl, propyl, cyano, hydroxymethyl, aminomethyl and trifluoromethyl;

and pharmaceutically acceptable derivatives thereof.

9. Compound of Claim 8 wherein \mathbb{R}^1 is selected from H, chloro or fluoro; wherein \mathbb{R}^2 is selected from

- 1,2,3,4-tetrahydro-isoquinolyl optionally substituted
 with one or more substituents selected from methyl,
 and Boc,
- 1,2,3,4-tetrahydro-quinolyl optionally substituted with one or more substituents selected from methyl, Boc and oxo,
- 2,3-dihydro-1H-indolyl optionally substituted with one or more substituents selected from methyl, 1-Boc-piperidin-4-ylmethyl piperidin-4-ylmethyl, 1-Boc-piperidin-4-yl, piperidin-4-yl, 1-methyl-piperidin-4-ylmethyl, 1-methyl-piperidin-4-yl, dimethylaminomethylcarbonyl, aminomethylcarbonyl, methylcarbonyl, pyrrolidin-2-ylmethyl, and 1-Boc-pyrrolidin-2-ylmethyl, and
- 3,4-dihydro-2H-benzo[1,4]oxazinyl optionally substituted with one or more substituents selected from methyl, and methylcarbonyl; and
- wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, cyano, methoxy, O-CH₂-O-, amino, trifluoromethyl, trifluoromethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminopropyl, and 3-(4-morpholinyl)propylamino;

15

10

5

20

25

and pharmaceutically

ceptable derivatives thereof.

10. Compound of Claim 8 wherein R^1 is selected from H, chloro or fluoro;

- wherein R² is selected from phenyl optionally substituted with one or more substituents selected from bromo, chloro, fluoro, morpholinylmethyl, 1-methylpiperazin-4-ylmethyl, 1-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1-
- methylpiperidin 4-ylmethyl, 2-methyl-2-(1-methylpiperidin-4-yl)ethyl, morpholinylethyl, 1-(4-morpholinyl)-2,2-dimethylpropyl, piperidin-4-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-
- piperidin-4-ylmethyl, piperidin-4-ylpropyl, 1-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, 1-Boc-pyrrolidin-2-ylmethyl, 4-methylpiperazin-1-yl, 4-
- methyl-1-piperidyl, 1-Boc-4-piperidyl, piperidin-4-yl, 1-methyl-(1,2,3,6-tetrahydropyridyl); methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, dimethylaminopropyl, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy,
- azetidin-3-ylmethoxy, 1-Boc-azetidin-3-ylmethoxy, pyrrol-1-ylethoxy, 1-methyl-pyrrol-2-ylmethoxy, pyrrol-2-ylmethoxy, 1-Boc-pyrrol-2-ylmethoxy, 1-Boc-piperdin-4-ylmethoxy, piperdin-4-ylmethoxy, and 1-methylpiperdin-4-yloxy;
- and wherein R⁸ is one or more substituents independently selected from H, chloro, fluoro, bromo, cyano, methoxy, O-CH₂-O-, amino, trifluoromethyl, trifluoromethoxy, 3-(4-morpholinyl)propyn-1-yl, dimethylaminopropyl, and 3-(4-morpholinyl)propylamino;

FŦ

O

qu

10

15

20-

25

and pharmaceutically acceptable derivatives thereof.

11. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound as in any of Claims 1-10.

12. A method of treating cancer in a subject, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

13. The method of Claim 12 comprising a combination with a compound selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents and miscellaneous agents.

- 14. A method of treating angiogenesis in a subject, said method comprising administering an effective amount of a compound as in any of Claims 1-10.
- 15. A compound as in any of Claims 1-10 for use in a method of therapeutic treatment for the human or animal body.
- 16. A method of treating KDR-related disorders in a mammal, said method comprising administering an effective amount of a compound as in any of Claims 1-10.
- 17. A method of treating proliferation-related
 30 disorders in a mammal, said method comprising administering an effective amount of a compound as in any of Claims 1-10.

add

50b Bl

that that I that and thus the little of

S B